MA, Hegazy, Abdelghani A, Ashoush O, and Lithy R. "Beneficial role of healthy eating Index-2015 score & physical activity on COVID-19 outcomes." BMC Nutrition 9, no. 113 (2023): 1-10.
application/pdf icons40795-023-00727-8.pdf
Hegazy, M. A., RMLithy, O. A. Ashoush, and A.Abdelghani. "COVID-19 disease outcomes:Does Gastrointestinal Burden play a role." Clinical and Experimental Gastroenterology 14 (2021): 199-207.
M. Hegazy, O.A.Ashoush, M.T.Hegazy, M.Wahba, and RMLithy. "Beyond probiotic legend:ESSAP gut microbiota health score to delineate SARS-COV-2 infection severity." British journal of Nutrition 127, no. 8 (2022): 1180-1189.
Hegazy, Mona A., Ibrahim Abd M. Elgwad, Soheir A. Abouelfadl, and Maha A. Hussein. "Serum Micro-RNA-122 level as a simple Noninvasive Marker of MAFLD severity." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 14 (2021): 2247-2254.
Hegazy, Mona A., Ibrahim Abd M. Elgwad, Soheir A. Abouelfadl, and Maha A. Hussein. "Serum Micro-RNA-122 level as a simple Noninvasive Marker of MAFLD severity." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 14 (2021): 2247-2254.
Hegazy, Mona A., Ibrahim Abd M. Elgwad, Soheir A. Abouelfadl, and Maha A. Hussein. "Serum Micro-RNA-122 level as a simple Noninvasive Marker of MAFLD severity." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 14 (2021): 2247-2254.
Hegazy, Mona A., Alshaimaa Rezk L. R. Alnaggar, Sherif M. Mogawer, and Rasha Abdel M. Samie. "Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 13 (2020): 3861-3872.
application/pdf iconcd_163_and_nash.pdf
M, Hegazy, Salah SA, Ezzat A, and Behiry ME. "Novel application of the traditional lipid ratios as strong risk predictor of NASH." Diabetes, Metabolic Syndrome and Obesity:Target and Therapy 2020, no. 13 (2020): 297-305.
Tourism